Avectas
Pre-clinicalAvectas is a cell engineering technology business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $37.5M
About
Avectas is a cell engineering technology business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies.
Cell TherapyGene Therapy
Funding History
2Total raised:$37.5M
Series B$27MJul 15, 2022
Series A$10.5MMar 15, 2020